1. Completed
Loading page
Mainboard
Mainboard issue. Listed.
Source: IPO Guru Pro
Company information, issue size, price band, lot size, minimum investment, and the dates published for this issue.
Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited at Pune on 23 June 2011. It became a wholly owned subsidiary of Glenmark Pharmaceuticals on 10 July 2018, and Glenmark's API business was spun off into it on 1 January 2019. It develops, makes and supplies APIs for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders and anti-infectives. It also offers contract development and manufacturing services to specialty pharma companies. It sells in India and exports to Europe, North America, Latin America and Japan. It has 4 plants, at Ankleshwar and Dahej in Gujarat and at Mohol and Kurkumbh in Maharashtra, with an installed capacity of 725.8 KL on 31 December 2020. The IPO was Rs 1,513.60 crore, with Rs 1,060.00 crore of fresh issue and Rs 453.60 crore of offer for sale by Glenmark Pharmaceuticals. Rs 800.00 crore of the fresh issue was planned for paying the promoter the outstanding consideration for the API business spin-off.
Current premium in rupees, the derived percentage, and the indicative price. History shows observed readings only. A missing premium is unavailable, not ₹0.
Grey Market Premium (GMP) is an unofficial market indicator and is not published by stock exchanges. Estimated listing values are illustrative, may change, and should not be considered a forecast or investment recommendation.
Subscription is shown in times subscribed. A missing multiple stays unavailable. A published zero is 0x.
Last updated: Unavailable
Last updated: Unavailable
Source: IPO Guru Pro Data by IPO Guru
History retrieved: 10 Nov 2026, 3:15 PM IST
No day-wise subscription history is loaded. Missing days are left blank and are not plotted as zero.
Source: IPO Guru Pro. History retrieved 10 Nov 2026, 3:15 PM IST.
Revenue and profit are in rupees for each reporting period. Assets, liabilities, and ratios use the source unit when the statement includes them. Missing figures stay blank.
| Metric (Rs. Crore) | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|
| Assets | 1,997.08 | 1,725.60 | 1,475.40 |
| Total Income | 1,885.98 | 1,549.30 | 886.87 |
| Profit After Tax | 351.58 | 313.10 | 195.59 |
Results may still be pending. Check Allotment opens the registrar allotment portal. You may need to select this IPO there. Sign-in is not required.
This is the actual change from the issue price to the listing price. It is separate from the unofficial GMP estimate. A missing price stays unavailable.
RHP, DRHP, and other links that passed the official address check. Unverified addresses are left out.
Data by IPO Guru · Updated
Glenmark Life Sciences makes active pharmaceutical ingredients for chronic therapy areas and offers contract development and manufacturing services. Its total income was Rs 1,885.98 crore in FY2021.
Glenmark Pharmaceuticals Ltd
1. Completed
2. Completed
3. Completed
4. Completed
Refund
Demat credit
Indicative only. A GMP-implied price is not a guaranteed listing price.
Unofficial grey-market premium in rupees. Missing observations are not connected and are not drawn as ₹0. This chart is not the listing gain.
High unavailable · Low unavailable
Tap a point for its rupee amount, percentage, and IST time. The table lists the same observations.
Source: IPO Guru Pro. History retrieved 10 Nov 2026, 3:15 PM IST.
| Observed (IST) | GMP (₹) | GMP % | Mark |
|---|---|---|---|
| 31 Jul 2021, 12:00 PM IST | ₹130 | +18.06% | None |
No intraday GMP history is loaded. Missing slots are not filled in.
High unavailable · Low unavailable
Source: IPO Guru Pro. History retrieved 10 Nov 2026, 3:15 PM IST.
| EBITDA | 591.89 | 483.95 | 248.16 |
| NET Worth | 752.75 | 401.69 | 88.13 |
| Reserves and Surplus | 750.79 | 399.73 | 86.17 |
| Total Borrowing | 0.00 | 0.02 | 0.02 |